Tag: Cannabinoid Biosynthesis
Exclusive Interview with Demetrix CEO Jeff Ubersax, PhD Biotechnology companies are hard at work finding ways to commercialize biosynthetic cannabinoids, and among those companies is Demetrix. CEO Jeff Ubersax...
Demetrix Secures $50 Million In Series A Funding To Provide Cannabinoids To Pharmaceutical, Supplement, And Consumer Product Companies Funding Round led by Tuatara Capital with Continued Participation by...
Intrexon Corporation and Surterra Wellness Partner in $100mm Deal to Advance Commercial Scale Fermentation-based Cannabinoid Production Exclusive Global Agreement to Transform Surterra’s Ability to Produce Specific Cannabinoids to Meet...
Exclusive Interview with Hyasynth Co-Founder and CEO Kevin Chen Right now, traditional agricultural practices are the main production method of natural cannabinoids. It takes months to create a final...
Exclusive Interview with Cellibre Founder and CEO Ben Chiarelli Cannabinoid biosynthesis is an emerging technology that holds the promise of producing THC, CBD, and other cannabinoids at a fraction...
This is a copy of the April 21st edition of our weekly Newsletter, which we have been publishing since October 2015. Happy Easter Friends! This is one of the...
Canadian investment bank AltaCorp Capital has published a research report explaining options for producing cannabinoids from sources beyond cannabis. Analyst and Managing Director David Kideckel, PhD, explained in “Synthetically-Derived...
This article was published originally at 420 Investor in October A highly disruptive technology that I have discussed over the past few years appears to be gaining traction. Biosynthesis,...
Organigram invests in Hyasynth Biologicals Inc., helps bring transformative “cellular agriculture” to Canadian cannabis industry Investment solidifies Organigram’s commitment to next generation delivery of cannabinoid products to global medical...
Cronos Group and Ginkgo Bioworks Announce a Landmark Partnership to Produce Cultured Cannabinoids BOSTON and TORONTO, Sept. 4, 2018 /PRNewswire/ – Today, Cronos Group Inc. (NASDAQ : CRON )...
Organigram Announces Letter of Intent for Strategic Investment in Hyasynth Biologicals Inc. Investment in Hyasynth Biologicals Inc. would advance Organigram’s interest in next generation cannabinoids MONCTON, NB, May 24,...
Librede Inc. Awarded Highly Competitive Phase II SBIR Grant from NIH February 13, 2018 CARLSBAD, Calif.–(BUSINESS WIRE)–Librede, an early stage biotechnology company, has been awarded a $1,490,000 Phase II...
Teewinot Life Sciences Corporation, a Global Leader in Pharmaceutical Cannabinoid Production, Secures $12.3 Million Series B Round Furthers Mission to Address Unmet Medical Needs Across the Globe NEW YORK...
Teewinot Life Sciences Corporation’s Subsidiary, Full Spectrum Laboratories, Ltd., Announced Today: Grant of an Important U.S. Patent with Broad Claims to Biosynthetic Production of Cannabinoids Furthers Mission to Address...
There is little doubt that cannabidiol (CBD) has medicinal benefits. Sanjay Gupta brought this into the mainstream in 2013 with his famous reversal, and, three years later, GW Pharma (NASDAQ:...
In September, the New York Times reported that THC can be produced from yeast. It turns out that not only THC but many of the cannabinoids as well as terpenes...
